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E-mail address: gray@salk.edu (P.C. Gray).Cripto is a small, GPI-anchored signaling protein that regulates cellular survival, proliferation, dif-
ferentiation and migration during normal developmental processes and tumorigenesis. Cripto func-
tions as an obligatory co-receptor for the TGF-b ligands Nodal, GDF1 and GDF3 but attenuates
signaling of others such as activin-A, activin-B and TGF-b1. Soluble, secreted forms of Cripto also
activate Src, ras/raf/MAPK and PI3K/Akt pathways via a mechanism that remains largely obscure.
This review describes the biological roles and signaling mechanisms of Cripto, highlighting our iden-
tiﬁcation of the 78 kDa glucose regulated protein (GRP78) as a cell surface receptor/co-factor
required for Cripto signaling via both TGF-b and Src/MAPK/PI3K pathways. We discuss emerging evi-
dence indicating that Cripto/GRP78 signaling regulates normal somatic stem cells and their tumor-
igenic counterparts.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction roles in regulating stem cell differentiation [2,5,6] and vertebrateThe TGF-b pathway is a ubiquitous regulator of myriad cellular
functions including proliferation, differentiation, apoptosis, migra-
tion and secretion. TGF-b signaling can have tumor suppressive or
oncogenic effects and despite a large body of work, the molecular
determinants of which outcome will prevail remain poorly under-
stood. Although simple at its core, consisting of TGF-b ligands, their
cognate transmembrane serine kinase receptors and intracellular
Smad proteins, the TGF-b pathway is ﬁnely tuned by a bewildering
array of modulators including ligand traps, co-receptors, inhibitory
Smads and Smad-associated transcriptional regulators. Given the
importance of the TGF-b pathway under normal physiological con-
ditions and in disease, it is critical to understand the roles and
molecular mechanisms of its modulators and to consider them as
therapeutic targets.
Cripto (Cripto-1, TDGF1) (Fig. 1A) is a small, GPI-anchored pro-
tein that modulates the signaling of several TGF-b ligands that sig-
nal via the Smad2/3 pathway. Cripto functions as an obligatory cell
surface co-receptor for a subset of ligands including Nodal [1,2],
GDF1 [3] and GDF3 [4]. This co-receptor function plays essentialchemical Societies. Published by E
GDF, growth and differentia-
8, glucose regulated protein
r 1; FRL-1, ﬁbroblast growthembryogenesis [1,2,7] and likely regulates normal tissue growth
and remodeling in adult tissues [8–11]. Cripto co-receptor function
has also been linked to tumor growth since Nodal signaling plays a
key role in promoting plasticity and tumorigenicity [12–15]. In
contrast to its co-receptor role, Cripto reduces the level of Smad
activation by activin-A [16–18], activin-B [18,19] and TGF-b1
[18,20–22], thereby inhibiting the cytostatic effects of these li-
gands [18,20–22]. Cripto also has signaling activities that are
thought to be independent of the TGF-b pathway [7,23]. The best
characterized of these is its growth factor-like activity in which
soluble/secreted forms of Cripto can lead to Src, ras/raf/MAPK
and PI3K/Akt pathway activation [7,23]. Cripto has also been re-
ported to promote signaling by Wnt [24] and Notch [25].
In an effort to further elucidate the molecular basis for Cripto
signaling, we conducted a screen aimed at identifying novel Cripto
interacting proteins [21]. This led to the identiﬁcation of GRP78
(Fig. 1B), an HSP70 family member and ER chaperone best known
for its coordination of the unfolded protein response (UPR) [26].
Although GRP78 is primarily targeted to the ER, a fraction of the
protein is localized to the plasma membrane where it has been
shown to have receptor-like function associated with increased
cellular proliferation and survival [27–29]. Cell surface Cripto/
GRP78 interaction is required for Cripto modulation of activin/No-
dal/TGF-b signaling and activation of Src/MAPK/PI3K pathways
[18,21]. This review provides an overview of Cripto function during
development and oncogenesis, focusing on its roles as a regulator
of the TGF-b pathway and its requirement for GRP78 as a celllsevier B.V. All rights reserved.
αβ
Fig. 1. Structural features and interacting partners of Cripto and GRP78. (A) Diagram of mouse Cripto indicating the locations of the signal peptide (SP), EGF-like domain, CFC
domain and GPI-anchor attachment site (GPI). Several TGF-b ligands including Nodal, activin-A and TGF-b1 have been shown to bind to the EGF-like domain of Cripto. The CFC
domain independently binds ALK4 and ALK7 and we have shown that it also binds GRP78. Monoclonal antibodies targeting either the EGF-like domain or the CFC domain
have been shown to have anti-tumor activity in vivo. (B) Diagram highlighting features shared by GRP78 and other Hsp70 family members including the ATP binding and
peptide-binding domains. Binding sites on GRP78 for Cripto and other extracellular proteins are indicated. N-20, C-20; polyclonal GRP78 antibodies (Santa Cruz
Biotechnology, Inc.); Ab39, mAb targeting cell surface GRP78 [130].
P.C. Gray, W. Vale / FEBS Letters 586 (2012) 1836–1845 1837surface signaling partner. We propose that targeting the Cripto/
GRP78 complex represents a promising therapeutic strategy for
the treatment of human tumors.
2. TGF-b pathway overview
The TGF-b superfamily contains over 30 secreted ligands in hu-
mans [30] and includes the activin [31], TGF-b [32], bone morpho-
genetic protein (BMP) [33] and Nodal-related families [1,2]. These
ligands control a wide array of cellular processes including prolif-
eration, homeostasis, differentiation, tissue morphogenesis, im-
mune responses, angiogenesis, wound repair and endocrine
function [31–35]. Disruption or dysregulation of TGF-b ligand sig-
naling is associated with multiple pathological states including tu-
mor growth and metastasis [36].
TGF-b superfamily members exert their biological effects by
interacting with two classes of transmembrane receptors possess-
ing serine/threonine kinase activities that are referred to as type I
and type II [37]. Following the characterization of the ﬁrst verte-
brate receptor serine/threonine kinase by our group, the activin
type II receptor (ActRII) [38], a dozen of these receptors are now
known to exist in human [37]. Type I receptors are referred to as
Activin receptor-Like Kinases (ALK1–7) [39–44]. The receptor acti-
vation mechanism was ﬁrst established for TGF-b and consists of
TGF-b binding to its type II receptor (TbRII) leading to the recruit-
ment, phosphorylation and activation of its type I receptor TbRI
(ALK5) [45]. A similar receptor activation mechanism has been
demonstrated for activin receptors in which activin binding to Ac-
tRII or ActRIIB is followed by recruitment, phosphorylation and
activation of the activin type I receptor ALK4 [46,47]. Notably, acti-
vin receptors are highly promiscuous and form signaling com-
plexes with activins as well as several other superfamily
members including Nodal, GDF1, GDF3 and myostatin (GDF8)
[48]. TGF-b ligand/receptor assembly triggers activation of the type
I receptor kinase which phosphorylates cytoplasmic Smad proteins
on C-terminal serine residues [49–52]. Activins, Nodal and TGF-bs
signal via Smad2 and Smad3 whereas BMPs signal via Smads 1, 5
and 8 [53]. Following phosphorylation by the type I receptor ki-
nase, receptor-regulated Smads form hetero-oligomeric complexes
with the common mediator Smad, Smad4, and then translocate to
the nucleus and interact directly with DNA and/or cell-type speciﬁc
co-activator or co-repressor proteins leading to the activation or
repression of target genes [54,55].3. Cellular effects of TGF-b ligands are context-dependent
Ligands that activate the Smad2/3 pathway can have variable
and even opposing effects on cellular proliferation, apoptosis and
differentiation depending on the cell type and the cellular context
[56]. The tumor suppressor function of the Smad2/3 pathway has
been well characterized and derives from its ability to inhibit the
cellular proliferation of multiple cell types and, in some cases, to
cause terminal differentiation or apoptosis [36]. Maintenance of
the cytostatic transcriptional program downstream of Smad2/3
pathway activation is critical for normal tissue homeostasis and tu-
mor suppression and disruptions or alterations in this pathway
have been observed in several types of human cancer [36]. Further-
more, following loss or attenuation of the cytostatic program, acti-
vation of the Smad2/3 pathway frequently has pro-tumorigenic
effects that are exacerbated in the context of activated stem cell/
growth factor pathways such as ras, Wnt and Notch [12,36,56–
61]. For example, tumor cells that have become refractory to the
cytostatic effects of TGF-b signaling generally secrete high levels
of TGF-b ligands that act in an autocrine/paracrine manner both
on tumor cells themselves and other cell types within the tumor
microenvironment including stromal ﬁbroblasts, endothelial cells
and immune cells. Activation of the Smad2/3 pathway in this con-
text can cause increased proliferation, motility, invasion and epi-
thelial to mesenchymal transition (EMT) of tumor cells as well as
increased angiogenesis and decreased immune surveillance
[12,36,56–61]. Since these effects can lead to increased tumor
growth and metastasis, intensive research efforts are currently
aimed at understanding the molecular mechanisms that cause this
cytostatic to oncogenic switch in Smad2/3 signaling.
4. Cripto modulates the TGF-b pathway during development
Nodal [35], GDF1 [3] and GDF3 [4] utilize activin signaling
receptors but differ from activins since they require co-receptors
from the Epidermal Growth Factor-Cripto, FRL-1, Cryptic (EGF-
CFC) protein family [3,35]. The EGF-CFC family consists of small,
glycosylated, extracellular signaling proteins including human
and mouse Cripto and Cryptic, Xenopus FRL-1 and zebraﬁsh one-
eyed pinhead (oep) [62,63]. Members of the EGF-CFC family have
an N-terminal signal peptide, an EGF-like domain, a cysteine-rich
CFC domain unique to the family and a C-terminal site for GPI
attachment [62,63] (Fig. 1A). The EGF-like domain binds Nodal
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and both of these interactions are required for Nodal signaling
[64,65]. Substantial biochemical evidence indicates that Nodal,
GDF1 and GDF3 bind Cripto and that these ligands require Cripto
or a related EGF-CFC co-receptor to form active signaling com-
plexes with activin receptors [3,4,8,64–66].
EGF-CFC proteins are known to act cell autonomously as an-
chored cell surface co-receptors but they also have activity when
expressed as soluble proteins lacking a GPI attachment site
[7,8,67,68] or when they are released from the cell surface follow-
ing enzymatic cleavage of their GPI anchors [65,69–71]. In this re-
gard, the GPI-cleaved form of Cripto was shown to be much more
active as a paracrine Nodal co-receptor than mutant forms of solu-
ble Cripto lacking the GPI attachment site [70]. In addition to its
cell surface roles, Cripto has also been reported to regulate intra-
cellular trafﬁcking and processing of Nodal [72] and Notch proteins
[25]. Genetic studies in zebraﬁsh and mice have shown that EGF-
CFC proteins are required for mesoderm and endoderm formation,
cardiogenesis, and the establishment of left/right asymmetry dur-
ing embryonic development [2,7,35,62,71,73]. Cripto knockout
mouse embryos lack a primitive streak and fail to form embryonic
mesoderm [74]. This phenotype is similar to that observed in Act-
RIIA/;ActRIIB/ mice [75], ALK4/ mice [76] and Nodal/ mice
[77,78], consistent with a requirement for coordinated Nodal sig-
naling via activin receptors and Cripto to initiate primitive streak
elongation and mesoderm formation [1,2]. Of note, Nodal activity
was observed in Cripto knockout mice during embryogenesis, sug-
gesting it can act independently of EGF-CFC co-receptors [79],
However, a subsequent study showed that the phenotype of Cripto;Fig. 2. Model of Cripto modulation of activin and Nodal signaling. (A) In the absence of Cr
genes responsive to both low and high levels of Smad2/3 signaling. (B) Cripto enables N
these ligands that are structurally and functionally similar. The weaker signaling of C
sustained levels of Smad2/3 signaling.Cryptic double mutant mice is virtually indistinguishable from that
of Nodal knockout mice, supporting the requirement of EGF-CFC
proteins for Nodal signaling. This work further provided evidence
that Cryptic can compensate for the absence of Cripto during early
embryogenesis by acting as a Nodal co-receptor in a non-cell
autonomous manner [71]. Thus, these data and other available evi-
dence strongly support a necessary role for EGF-CFC co-receptors
as mediators of Nodal signaling in most, if not all, circumstances.
Cripto has also been recognized as a cell surface marker selec-
tively expressed in embryonic stem cells [80–82] and iPS cells
[83–85] and both Nodal and Cripto have been shown to play
important roles as regulators of stem cell pluripotency mainte-
nance and differentiation [5–7,82,86,87]. Although it is predomi-
nantly expressed during embryogenesis, Cripto has recently been
shown to regulate developmental processes in adult tissues. Cripto
was shown to function as a key regulator of hematopoietic stem
cells (HSCs) within the hypoxic niche and to maintain the stem cell
potential of HSCs ex vivo [88]. Cripto was also recently reported to
regulate myostatin signaling in myoblasts derived from adult
mouse muscle tissue [11]. Cripto expression has been reported in
several other adult tissues including mammary gland [8], adipose
tissue [9], pancreas [89] and endometrium [10,90], suggesting it
may have a broad role in regulating adult tissue stem cells.
5. Cripto regulation of activin/Nodal signaling
As mentioned above, Cripto has the interesting property of act-
ing as a co-receptor for certain TGF-b ligands while inhibiting the
signaling of others. Careful analysis demonstrated dose-dependentipto, Nodal cannot signal and activin can signal at high levels leading to activation of
odal signaling and attenuates activin signaling and forms receptor complexes with
ripto-containing complexes precludes the regulation of genes that require high,
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by Cripto [17] despite the fact that these ligands are closely related
structurally and utilize the same signaling receptors. Incremental
increases in Cripto expression progressively inhibited maximal
activin-A signaling to 50% of its original levels at which point
higher levels of Cripto expression had no further effect [17]. These
observations suggest that Cripto functions as a non-competitive
activin antagonist rather than as a competitive antagonist as had
been previously proposed [16,19,91]. Interestingly, maximal Nodal
signaling was indistinguishable from that of activin in the presence
of high levels of Cripto, i.e., 50% of maximal activin-A signaling in
the absence of Cripto [17]. This discovery that activin is capable of
signaling at higher levels than Nodal is consistent with the ﬁnding
that activin regulates nearly twice as many genes as Nodal during
Xenopus development including cell cycle genes associated with
its antiproliferative role during gastrulation [92]. Since activin-A
and Nodal each elicited similar maximal signaling responses in
the presence of Cripto, we hypothesized that both ligands form
structurally similar signaling complexes containing Cripto and
activin receptors. In support of this, covalent crosslinking experi-
ments demonstrated that activin-A assembles complexes contain-
ing Cripto, ActRII and ALK4 when these proteins were
overexpressed in 293T cells or when they were expressed at
endogenous levels in P19 cells [17]. Furthermore, Nodal could
compete with activin-A for assembly of Cripto/ActRII/ALK4 com-
plexes and bound the same site as activin-A on ActRII [17]. To-
gether, these results indicate that activin and Nodal assemble
structurally and functionally similar signaling complexes contain-
ing ActRII, ALK4 and Cripto. Our signaling data also indicate that
these Cripto-containing complexes are less active than receptor
complexes assembled by activin in the absence of Cripto. We have
proposed a model in which the opposing effects of Cripto on activin
and Nodal signaling stem from the ability of Cripto to act as an
obligatory Nodal co-receptor on the one hand and non-competitive
activin antagonist on the other despite the fact that it forms similar
receptor complexes with both ligands [17] (Fig. 2). Thus, by either
promoting or attenuating the signaling of TGF-b ligands that utilize
the Smad2/3 pathway, Cripto can regulate expression patterns and
cell fate decisions that are highly sensitive to the magnitude and
duration of Smad2/3 signaling [93–95] (Fig. 2).6. Cripto modulation of the TGF-b pathway during oncogenesis
In addition to its physiological roles during development, Cripto
has also been implicated in tumorigenesis. Cripto was originally
isolated as a putative oncogene from a human teratocarcinoma cell
line [96] and is expressed at high levels in human breast, colon,
stomach, pancreas, lung, ovary, endometrial, testis, bladder and
prostate tumors though negligibly expressed in the normal tissue
counterparts of these tumors [63]. Soluble Cripto is also detected
in plasma from patients with breast or colon carcinoma at levels
that were signiﬁcantly elevated relative to those of healthy volun-
teers, indicating Cripto may represent a novel biomarker for detec-
tion of these cancers [97]. Cripto was expressed at high levels in
tumors from neu (ErbB2), TGF-a, int-3, polyoma middle T (PyMT)
and simian virus 40 large T antigen [98] transgenic mice and also
from Smad7/v-rasHa mice where Cripto was proposed to promote
the malignant phenotype [99]. Early studies demonstrated that
Cripto has a transforming ability since its overexpression could
confer anchorage independent growth to mammary epithelial cells
[100]. Cripto has subsequently been shown to have multiple onco-
genic functions including promotion of cellular proliferation, sur-
vival, migration, invasion, angiogenesis and EMT [7]. Cripto also
functions as an oncogene in vivo since transgenic MMTV-Cripto
and WAP-Cripto mice develop mammary hyperplasias and tumors[7,101–103] and since monoclonal antibodies targeting Cripto re-
duce the growth of tumor xenografts in nude mice [19,104]. There-
fore, in addition to its developmental roles, Cripto can promote
tumorigenesis and is selectively expressed in human tumors.
Cripto is thought to promote oncogenesis via modulation of
TGF-b ligand signaling and through mechanisms that are indepen-
dent of TGF-b ligands and their signaling receptors [7,23,48]. As a
modulator of TGF-b ligand signaling, Cripto can promote the
tumorigenic phenotype either as a co-receptor for receptor activa-
tion or through attenuation of cytostatic pathway activation [12–
16,18–22,91,105–107]. The oncogenicity of Cripto in its role as
an obligatory co-receptor is indicated by several studies showing
that Nodal promotes tumor cell growth, aggressiveness and plas-
ticity [12–15,106,107]. Pioneering studies in human melanoma
showed that Nodal is secreted from aggressive melanoma cells
and that blockade of Nodal signaling inhibited melanoma cell inva-
siveness, colony forming ability and tumorigenicity [12]. Nodal
expression and tumorigenicity were also reduced in melanoma
and breast cancer cell lines when they were grown in an embry-
onic microenvironment containing the Nodal antagonist Lefty
[13]. Nodal was subsequently found to be expressed in cancerous
but not normal prostate specimens and its overexpression in pros-
tate cancer cell lines enhanced anchorage independent growth
while inhibiting AR signaling and down regulating the expression
of androgen-responsive genes [106]. In glioma cell lines, Nodal
was shown to cause increased cell invasiveness, proliferation and
tumor growth, while Nodal knockdown caused differentiation of
these cells toward an astrocytic phenotype [14]. Nodal knockdown
was also shown to inhibit angiogenesis and VEGF expression in tu-
mors derived from glioma cell lines [107]. Finally, Nodal and acti-
vin signaling were recently reported to promote self-renewal and
tumorigenicity of pancreatic cancer stem cells [15]. In each of these
studies, Cripto expression was detected in the Nodal-responsive
cells [12–15,106,107] and, importantly, Cripto and Nodal were
each shown to be selectively expressed in the tumorigenic stem
cell compartment of pancreatic cancer [15]. Together, these studies
clearly indicate the important role of Cripto-dependent Nodal sig-
naling in promoting cellular plasticity and tumorigenesis.
Cripto can also attenuate the cytostatic, tumor suppressive ef-
fects of activin and TGF-b signaling. We originally showed that Cri-
pto binds activin-A and attenuates activin-A signaling and, based
on these ﬁndings, hypothesized that Cripto exerts its oncogenic ef-
fects at least in part by inhibiting the tumor suppressor function of
the Smad2/3 pathway [16]. In support of this, it was reported that
Cripto also binds activin-B and, importantly, that it inhibits cyto-
static Smad2/3 signaling downstream of both activin-A and acti-
vin-B [18,19]. Similar to what was shown with activins, we
showed that Cripto binds TGF-b1 and reduces TGF-b1 crosslinking
to its type I receptor, TbRI [20]. This suggested a role for Cripto in
altering or disrupting TGF-b receptor assembly and, consistent
with this, Cripto overexpression inhibited TGF-b-dependent Smad2
phosphorylation and antiproliferative effects in human mammary
epithelial MCF10A cells. Cripto knockdown in HeLa cells enhances
TGF-b1 signaling indicating a role for endogenous Cripto as a TGF-b
antagonist [20]. Together, these results demonstrate that Cripto
binds TGF-b1 in a complex with TbRII, inhibits TGF-b receptor
assembly and reduces downstream Smad2/3 signaling and cyto-
static effects. Cripto antagonism of TGF-b signaling has subse-
quently been observed in embryonal carcinoma NCCIT cells, [18]
hematopoietic stem cells [88] and in keratinocytes, where its
antagonism of TGF-b signaling was cited as a potential mechanism
underlying skin carcinogenesis [22].
Thus, Cripto can have oncogenic effects both as a co-receptor
and as an antagonist of TGF-b signaling. We propose that overall,
Cripto modulation of the TGF-b pathway promotes tumorigenesis
by establishing and enforcing low to moderate levels of Smad2/3
1840 P.C. Gray, W. Vale / FEBS Letters 586 (2012) 1836–1845signaling while preventing high, sustained Smad2/3 signaling. As
described above, in the presence of Cripto, Nodal and activin
achieved signaling maxima that were indistinguishable from each
other but only 50% of maximal activin signaling in the absence of
Cripto [17]. Similarly, TGF-b signaling appeared to be only partially
inhibited even at high levels of Cripto expression [20]. These obser-
vations are noteworthy since high, sustained levels of Smad2/3 sig-
naling are required to initiate and maintain the cytostatic program
while lower levels of Smad2/3 signaling elicit transcription of
genes associated with tumor progression [56,108]. This is consis-
tent with available data that have shown that in the presence of
Cripto, TGF-b and activin lose their cytostatic effects but acquire
oncogenic signaling properties similar to those of Nodal deriving,
at least in part, from their similar ability to activate the Smad2/3
pathway at low levels [17,18].
7. Cripto has growth factor activity independent of the TGF-b
pathway
In addition to its effects on TGF-b superfamily ligands, Cripto
has multiple signaling activities that are thought to be indepen-
dent of TGF-b ligands and receptors. These include its function as
a soluble growth factor that can be negatively regulated by caveo-
lin-1 [109], its role as a co-receptor for Wnt signaling [24] and its
ability to promote Notch processing [25]. Pioneering studies dem-
onstrated that soluble Cripto activates both the mitogen activated
protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)
pathways [7,110,111]. Treatment of HC-11 mammary epithelial
cells with soluble Cripto resulted in tyrosine phosphorylation of
the SH2-adaptor protein Shc, association of Shc with Grb2 and acti-
vation of the p42/44 Erk/MAPK pathway [112]. Treatment of cells
with soluble Cripto also caused phosphorylation of the p85 regula-
tory subunit of PI3K leading to phosphorylation and activation of
Akt in SiHa cervical carcinoma cells [111]. The receptor mechanism
mediating these Cripto effects has remained elusive. Although Cri-
pto treatment induced tyrosine phosphorylation of ErbB4, it was
unable to directly bind ErbB4 or other members of the EGF recep-
tor family [112]. In addition, while soluble forms of Cripto have
been reported to cause Smad2 phosphorylation in an ALK4- and
Nodal-dependent manner, activation of MAPK/PI3K pathways by
soluble Cripto was reported to be ALK4- and Nodal-independent
[113]. Subsequent studies showed that Src is activated following
treatment of cells with soluble Cripto and that Src activation is nec-
essary for Cripto-dependent activation of MAPK and PI3K path-
ways [114]. The GPI-anchored proteoglycan glypican-1 was also
reported to bind Cripto and facilitate Cripto-dependent Src activa-
tion [114]. However, the transmembrane signaling mechanism
coupling Cripto to activation of Src and MAPK/PI3K pathways has
not yet been elucidated.8. GRP78, a putative Cripto signaling partner
The mechanisms of Cripto’s many signaling functions are only
partially understood at the molecular level. Therefore, in order to
better understand Cripto signaling function, we sought to identify
and characterize additional Cripto binding partners. We conducted
a protein–protein interaction screen using Cripto as bait and these
efforts led to the identiﬁcation of the HSP70 family member GRP78
as a novel Cripto binding protein [21]. Fig. 1B illustrates the struc-
tural features of GRP78 including the ATP binding (ATPase) and
peptide-binding domains that are highly conserved among HSP70
family members and that mediate classical chaperone functions
[115,116] (Fig. 1B).
GRP78 is best known for its roles in the ER where it promotes
the folding, maturation and assembly of nascent proteins and alsocoordinates the unfolded protein response (UPR) that alleviates ER
stress [26,117]. Although it is constitutively expressed, GRP78 lev-
els increase greatly in response to demanding conditions such as
hypoxia and nutrient deprivation and it has been heavily impli-
cated in cytoprotection and chemoresistance in the tumor micro-
environment where these conditions prevail [118,119]. Similar to
Cripto knockout mice, GRP78 knockout mice have an early embry-
onic lethal phenotype and GRP78 was found to be required for pro-
liferation and survival of embryonic inner cell mass cells that are
the precursors of pluripotent stem cells [120]. Cripto is a critical
regulator of cardiogenesis [5,121,122] and, interestingly, both
GRP78 [123] and Cripto [124] are expressed in the embryonic
heart. This raises the possibility that GRP78 may be required for
Cripto function during cardiac development. Like Cripto, GRP78 is
highly elevated in multiple types of solid tumors relative to their
normal tissue counterparts [26,118,119] and this may reﬂect the
aforementioned stress responsive and protective properties. The
ﬁrst direct evidence for the involvement of GRP78 in cancer pro-
gression came from the demonstration that GRP78 knockdown in
ﬁbrosarcoma cells using antisense prevented tumor formation in
nude mice [125]. It was further shown that a suicide transgene dri-
ven by the GRP78 promoter in breast cancer cells completely
blocked tumor growth in mice [126]. More recently, it was demon-
strated that GRP78 heterozygous mice develop normally but are
resistant to transgene-induced mammary tumor growth [127]. In
this study, it was demonstrated that reduced GRP78 levels in het-
erozygous mice resulted in decreased tumor cell proliferation, in-
creased tumor cell apoptosis and reduced tumor angiogenesis
[127]. Therefore, it is reasonable to infer that the conditions found
within solid tumors cause induction of GRP78 and that its expres-
sion enhances tumor growth.
Since Cripto is a GPI-anchored extracellular protein, it was sur-
prising for us to discover that it interacts with a protein localized to
the ER. However, it has now been widely reported that a fraction of
GRP78 localizes to the plasma membrane [27–29]. Cell surface
GRP78 was ﬁrst detected in human rhabdomyosarcoma cells fol-
lowing treatment with thapsigargin, a potent inducer of GRP78
expression [128]. Global proﬁling of the cell surface proteome of
cancer cells also identiﬁed GRP78 [129]. Furthermore, phage dis-
play-derived human monoclonal antibodies isolated based on their
ability to bind to the surface of live primary human breast cancer
cells were shown to speciﬁcally recognize GRP78 [130]. GRP78
can exist as a transmembrane protein [131] but it was also isolated
as a soluble factor secreted by tumor cells and exerting pro-sur-
vival effects on endothelial cells and myeloma cells [132]. Regard-
less of its topology, GRP78 actively accumulates at the cell surface
following induction by ER stress or ectopic expression [133] and
several extracellular proteins have been reported to bind cell sur-
face GRP78 near its N- or C-terminus [21,130,134–137] (Fig. 1C).
Importantly, cell surface GRP78 signaling functions appear to be
diversiﬁed and include acting as a co-receptor for viruses and
MHC Class I antigen presentation [138] and as a receptor for Krin-
gle 5 of plasminogen [134] and activated a2-macroglobulin (a2M)
[139]. Interestingly, a2M binding to GRP78 on the surface of pros-
tate carcinoma 1-LN cells triggered pro-proliferative and anti-
apoptotic behavior via activation of MAPK and PI3K pathways
[139,140]. Cell surface GRP78 was similarly shown to have an
essential role in mediating T-cadherin signaling via Akt and result-
ing pro-survival effects in endothelial cells [135]. Consistent with
these studies, tumorigenesis and Akt activation resulting from Pten
loss was blocked by conditional knockout of GRP78 expression
both in prostate epithelium [141] and the hematopoietic system
[142]. Signiﬁcantly, GRP78 autoantibodies were isolated from the
serum of prostate cancer patients and the reactivity of these anti-
bodies to cell surface GRP78 correlated strongly with androgen
insensitivity, increased cancer aggressiveness and decreased
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cally targeting cell surface GRP78 prevented the growth of breast
and prostate tumors in mice [144,145]. Finally, targeting cell sur-
face GRP78 inhibited stemness, radioresistance and tumorigenicity
of head and neck cancer initiating cells [146].
9. Cripto/GRP78 signaling via TGF-b and Src/MAPK/PI3K
pathways
Since Cripto is a cell surface protein and GRP78 is primarily
localized to the ER, we ﬁrst sought to determine whether GRP78
interacts with Cripto at the cell surface. We overexpressed Cripto
and GRP78 in 293T cells, labeled cell surface proteins with cell
impermeable biotin and subjected cell lysates to anti-Cripto
immunoprecipitation followed by blotting with avidin-HRP.
GRP78 co-immunoprecipitated with Cripto in this experiment
and was biotinylated indicating Cripto and GRP78 associate at
the cell surface. Endogenously expressed Cripto and GRP78 also
interact at the cell surface as indicated by their co-immunoprecip-
itation from biotin-treated P19 cells [21]. Consistent with these
data, immunoﬂuorescence studies showed that Cripto and GRP78
co-localize at the cell surface when overexpressed in 293T cells
and when expressed at endogenous levels in P19 cells [21].
Based on available evidence indicating cell surface GRP78 and
Cripto may have similar functions, we hypothesized that GRP78
and Cripto interact as signaling partners. In support of this,
GRP78 knockdown in HeLa cells enhanced TGF-b1-induced Smad2
phosphorylation [21] in a manner that was similar to the effect of
Cripto knockdown in the same cells [20]. GRP78 did not directly
interact with TGF-b type I and type II receptors suggesting it exerts
its effects on TGF-b signaling via its interaction with Cripto. Impor-
tantly, Cripto and GRP78 functioned collaboratively to inhibit cyto-
static TGF-b signaling since overexpression of both proteins
reduced TGF-b1-dependent Smad2 phosphorylation and growth
inhibition to a much greater extent than overexpression of either
protein alone [21]. Cripto and GRP78 also acted together to in-
crease colony growth and attenuate the growth inhibitory effects
of TGF-b1 on PC3 cells in soft agar. Together, these data indicateFig. 3. Cripto binding to cell surface GRP78 promotes stemness and the tumorigenic ph
regulation of the Smad2/3 pathway both as a Nodal co-receptor and antagonist of activin
of PI3K and MAPK signaling via activation of Src. The effects of Cripto/GRP78 signaling
promote stemness, plasticity and tumorigenesis. (B) The N-20 antibody blocks Cripto bin
and Smad2/3 pathways. By blocking Cripto, this GRP78 antibody blocks Src/MAPK/PI3K
cytostasis and tumor suppression.that Cripto and GRP78 form a complex at the cell surface that pro-
motes cell growth and inhibits cytostatic TGF-b signaling [21].
In subsequent studies, we tested the requirement of cell surface
GRP78 for Cripto signaling and biological activity. Like mouse P19
cells, human germ cell tumor-derived NCCIT cells express high lev-
els of Cripto endogenously and we analyzed Cripto signaling in
NCCIT lines stably transduced with empty vector, Cripto shRNA,
GRP78 shRNA or both shRNAs [18]. Cripto knockdown or GRP78
knockdown similarly enhanced activin-A, activin-B and TGF-b1
signaling while inhibiting Nodal signaling and knockdown of both
proteins had a more pronounced effect than knockdown of either
alone [18]. Furthermore, an antibody (N-20, Santa Cruz Biotechnol-
ogy, Inc.) previously shown to block cell surface GRP78 signaling
functions [134,135] blocked Cripto effects on activin-A, activin-B,
TGF-b1 and Nodal signaling. Thus, treatment of NCCIT control cells
with the N-20 antibody enhanced activin-A, activin-B and TGF-b1
signaling and decreased Nodal signaling in a manner similar to that
of Cripto knockdown or GRP78 knockdown. Also, this GRP78 anti-
body had no effect on signaling by activin/TGF-b/Nodal in Cripto
knockdown cells indicating it exerts its effects by blocking Cripto.
We explored the mechanistic basis for these effects and showed
that deletion of the N-terminal N-20 epitope on GRP78 disrupts
Cripto/GRP78 binding and also that Cripto and the N-20 antibody
compete for binding to GRP78 [18]. Signiﬁcantly, the N-20 anti-
body also increased activin-A signaling and decreased Nodal sig-
naling in hES cells as measured by Smad2 phosphorylation [18].
Together, these ﬁndings indicate that GRP78 is required for Cripto
signaling via the TGF-b pathway and provide the ﬁrst evidence for
Cripto/GRP78 signaling in ES cells.
As discussed above, soluble forms of Cripto activate Src/MAPK/
PI3K pathways and we tested if cell surface GRP78 is also required
for this Cripto growth factor-like activity. In support of this possi-
bility, we showed that treatment with soluble Cripto protein
caused Akt, Erk and Src phosphorylation in Cripto knockdown
NCCIT cells, but not in cells in which both Cripto and GRP78 were
knocked down [18]. Furthermore, and similar to what was ob-
served with Cripto regulation of TGF-b ligands, the N-20 antibody
blocked Cripto-induced Akt phosphorylation and cellularenotype. (A) The cell surface Cripto/GRP78 complex interaction required for Cripto
and TGF-b signaling. Soluble Cripto also binds cell surface GRP78 to cause activation
on Src/MAPK/PI3K and Smad2/3 pathways are likely to function synergistically to
ding to cell surface GRP78 and inhibits Cripto-dependent signaling via MAPK, PI3K
pathway activation and enhances activin and TGF-b signaling thereby promoting
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Akt and Src phosphorylation and inhibited Cripto-induced pro-pro-
liferative and EMT-like effects in MCF10A human mammary epi-
thelial cells [18]. Interestingly, Cripto/GRP78 signaling inhibited
cytostatic effects of activin and TGF-b and promoted pro-prolifera-
tive responses to activin, TGF-b and Nodal in both MCF10A cells
and in NCCIT cells [18,21]. The molecular basis for this switch in
the proliferative effects of activin/Nodal/TGF-b signaling remains
to be elucidated, but likely derives from low/moderate Smad2/3
signaling coupled with activated Src/MAPK/PI3K signaling. In sum-
mary, our results indicate that cell surface GRP78 functions as a
critical mediator of Cripto signaling via both TGF-b and Src/
MAPK/PI3K pathways (Fig. 3) and they suggest that GRP78 is likely
required for Cripto function generally.
Subsequent to our studies, other groups further implicated Cri-
pto signaling via cell surface GRP78 both in the regulation of head
and neck cancer tumor initiating cells [146] and in normal adult
hematopoietic stem cells [88]. Wu et al. [146] showed that cell sur-
face GRP78 is co-expressed with Cripto in head and neck cancer
initiating cells (HN-CIC), a tumorigenic subpopulation of head
and neck squamous cell carcinoma. Knockdown of cell surface
GRP78 reduced the self-renewal properties and tumorigenicity of
HN-CIC consistent with a role for Cripto signaling via GRP78 to pro-
mote tumor initiation and stemness in these cells [146]. However,
the importance of Cripto/GRP78 interaction in promoting stemness
and tumorigenicity of HN-CIC remains to be directly demonstrated.
More recently, a critical and direct role for Cripto/GRP78 signaling
in adult hematopoietic stem cells (HSC) was identiﬁed. Miharada
et al. [88] demonstrated that HSCs contain GRP78+ and GRP78
subpopulations and that only the GRP78+ population is responsive
to Cripto treatment. Cripto treatment activated the PI3K/Akt path-
way in these cells and maintained the stem cell potential of the
GRP78+ population ex vivo as evidenced by its ability to promote
multilineage colony growth in vitro and reconstitution of the
hematopoietic system upon transplantation [88]. Signiﬁcantly,
the Cripto effects on HSCs were completely blocked if cells were
treated with the N-20 GRP78 antibody [88]. Overall, the authors
showed that Cripto/GRP78 signaling represents a critical down-
streammediator of HIF-1a required for maintenance of undifferen-
tiated HSC in hypoxic niche in bone [88]. This study substantiates
the requirement of cell surface GRP78 as a Cripto signaling partner
and with an increasing literature on both Cripto and cell surface
GRP78 suggests the potential for similar Cripto/GRP78 signaling
in stem cell maintenance in other adult tissue types.
Overall, available evidence supports a model in which the cell
surface Cripto/GRP78 complex acts as a signaling node that pro-
motes cellular plasticity and the tumorigenic phenotype (Fig. 3A).
According to this model, Cripto and GRP78 cooperatively attenuate
cytostatic Smad2/3 signaling in response to activin and TGF-b and
cause activin, Nodal and TGF-b to promote stemness and oncogen-
esis through coordination of restricted Smad2/3 signaling and acti-
vation of Src, MAPK and PI3K pathways. The N-20 GRP78 antibody
blocks Cripto binding to cell surface GRP78 and thereby inhibits
Cripto signaling via both Smad2/3 and Src/MAPK/PI3K pathways
[18] (Fig. 3B).
10. Conclusions
Collectively, the evidence outlined above supports a role for Cri-
pto signaling via cell surface GRP78 to promote stemness and plas-
ticity during normal development and tumor progression. At the
molecular level, Cripto acts via GRP78 to alter TGF-b signaling
either directly, by forming complexes with TGF-b ligands and their
signaling receptors, or indirectly by activating Src/MAPK/PI3K and
possibly Notch and Wnt pathways which can then engage incrosstalk with the Smad2/3 pathway. We propose that the cell sur-
face Cripto/GRP78 complex acts via these direct and indirect mech-
anisms to cause a switch in Smad2/3 signaling from cytostatic to
oncogenic.
Available data clearly indicate that Cripto binding to cell surface
GRP78 is required for Cripto signaling. Therefore, molecules that
interfere with Cripto signaling, such as caveolin-1, may do so by
interfering with Cripto/GRP78 binding. However, the mechanistic
details of how GRP78 enables Cripto signaling remain to be eluci-
dated. One possibility is that GRP78 serves as an adaptor protein
that physically couples Cripto to signaling targets such as TGF-b li-
gands/receptors and tyrosine kinase receptors such as erbB4. In
such a role, GRP78 could act either as an extracellular protein or
as a transmembrane protein. However, as a transmembrane pro-
tein, GRP78 may possess a cytoplasmic domain capable of activat-
ing downstream signaling independently of coupling to other
receptors. Perhaps a more likely scenario is that extracellular
GRP78 acts in its capacity as a chaperone and that Cripto is one
of its client proteins. This is supported by the fact that GRP78 binds
a large variety of extracellular proteins and regulates multiple di-
verse signaling processes. Furthermore, secreted GRP78 can regu-
late cell signaling in a non-cell autonomous manner. Future
studies will be required to clarify the precise mechanism through
which cell surface GRP78 facilitates Cripto signaling.
In summary, Cripto regulates the signaling of several TGF-b
superfamily members that activate the Smad2/3 pathway and acti-
vates Src/MAPK/PI3K and Wnt/Notch pathways. GRP78 forms a
complex with Cripto at the cell surface and this interaction appears
to be essential for all aspects of Cripto signaling. Cripto/GRP78 sig-
naling is emerging as a key regulator of stem cell function and
tumorigenesis and targeting the cell surface Cripto/GRP78 complex
represents an attractive therapeutic strategy for the treatment of
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